Androgenic control of transforming growth factor-β signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-β receptor II

Cancer Research

Volumn 68, Issue 19, 2008, Pages 8173-8182

  Song, Kyung ^a   Wang, Hui ^a   Krebs, Tracy L ^a   Kim, Seong Jin ^a,b   Danielpour, David ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Gachon University College of Medicine   (South Korea)

^c Wolstein Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ALPHA DIHYDROTESTOSTERONE; CASPASE 3; CYCLIN D; PLASMINOGEN ACTIVATOR; PROTEIN BCL XL; TESTOSTERONE; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL DEATH; DOWN REGULATION; ENZYME ACTIVATION; GEL MOBILITY SHIFT ASSAY; GENE REPRESSION; HORMONAL REGULATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE EPITHELIUM; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

ANDROGENS; APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CELLS, CULTURED; CYCLIN D; CYCLINS; CYTOPROTECTION; DIHYDROTESTOSTERONE; DOWN-REGULATION; EPITHELIAL CELLS; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 54249106830     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2290     Document Type: Article

References (44)

1. Roberts AB, Sporn MB. The transforming growth factor β. New York: Springer-Verlag; 1990.
2. Roberts AB, Wakefield LM. The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci U S A 2003;100:8621-3.
3. Guo Y, Kyprianou N. Restoration of transforming growth factor β signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 1999;59:1366-71.
4. Tang B, de Castro K, Barnes HE, et al. Loss of responsiveness to transforming growth factor β induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res 1999;59:4834-42.
5. Song K, Cornelius SC, Danielpour D. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor β receptor type II. Cancer Res 2003;63:4358-67.
6. Bhowmick NA, Chytil A, Plieth D, et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848-51.
7. Tu WH, Thomas TZ, Masumori N, et al. The loss of TGF-β signaling promotes prostate cancer metastasis. Neoplasia 2003;5:267-77.
8. Wrana JL, Attisano L. The Smad pathway. Cytokine Growth Factor Rev 2000;11:5-13.
9. Massague J, Chen YG. Controlling TGF-β signaling. Genes Dev 2000;14:627-44.
10. Itoh S, ten Dijke P. Negative regulation of TGF-β receptor/Smad signal transduction. Curr Opin Cell Biol 2007;19:176-84.
11. Chipuk JE, Cornelius SC, Pultz NJ, et al. The androgen receptor represses transforming growth factor-β signaling through interaction with Smad3. J Biol Chem 2002;277:1240-8.
12. Danielpour D, Song K. Cross-talk between IGF-I and TGF-β signaling pathways. Cytokine Growth Factor Rev 2006;17:59-74.
13. Song K, Krebs TL, Danielpour D. Novel permissive role of epidermal growth factor in transforming growth factor β (TGF-β) signaling and growth suppression. Mediation by stabilization of TGF-β receptor type II. J Biol Chem 2006;281:7765-74.
14. Veldscholte J, Berrevoets CA, Zegers ND, van der Kwast TH, Grootegoed JA, Mulder E. Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry 1992;31:7422-30.
15. Ohara-Nemoto Y, Nemoto T, Sato N, Ota M. Characterization of the nontransformed and transformed androgen receptor and heat shock protein 90 with high-performance hydrophobic-interaction chromatography. J Steroid Biochem 1988;31:295-304.
16. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002;23:175-200.
17. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
18. Burd CJ, Morey LM, Knudsen KE. Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer 2006;13:979-94.
19. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 2008;6:e001.
20. Bruckheimer EM, Kyprianou N. Dihydrotestosterone enhances transforming growth factor-β-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology 2001;142:2419-26.
21. Hayes SA, Zarnegar M, Sharma M, et al. SMAD3 represses androgen receptor-mediated transcription. Cancer Res 2001;61:2112-8.
22. Kang HY, Huang KE, Chang SY, Ma WL, Lin WJ, Chang C. Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J Biol Chem 2002;277:43749-56.
23. Gerdes MJ, Dang TD, Larsen M, Rowley DR. Transforming growth factor-β1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells. Endocrinology 1998;139:3569-77.
24. Kyprianou N, Isaacs JT. Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989;3:1515-22.
25. Kyprianou N, Isaacs JT. Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens. Endocrinology 1988;123:2124-31.
26. Kim IY, Ahn HJ, Zelner DJ, Park L, Sensibar JA, Lee C. Expression and localization of transforming growth factor-β receptors type I and type II in the rat ventral prostate during regression. Mol Endocrinol 1996;10:107-15.
27. Brodin G, ten Dijke P, Funa K, Heldin CH, Landstrom M. Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res 1999;59:2731-8.
28. Danielpour D. Functions and regulation of transforming growth factor-β (TGF-β) in the prostate. Eur J Cancer 2005;41:846-57.
29. Kundu SD, Kim IY, Yang T, et al. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)-TGF-β type II dominant negative receptor. Prostate 2000;43:118-24.
30. Lucia MS, Sporn MB, Roberts AB, Stewart LV, Danielpour D. The role of transforming growth factor-β1, -β2, and -β3 in androgen-responsive growth of NRP-152rat prostatic epithelial cells. J Cell Physiol 1998;175:184-92.
31. Danielpour D, Kadomatsu K, Anzano MA, Smith JM, Sporn MB. Development and characterization of non-tumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res 1994;54:3413-21.
32. Bonham MJ, Danielpour D. Improved purification and yields of RNA by RNeasy. Biotechniques 1996;21:57-60.
33. Song K, Wang H, Krebs TL, Danielpour D. Novel roles of Akt and mTOR in suppressing TGF-β/ALK5-mediated Smad3 activation. EMBO J 2006;25:58-69.
34. Song K, Krebs TL, Danielpour D. Novel Permissive role of epidermal growth factor in transforming growth factor β (TGF-β) signaling and growth suppression: mediation by stabilization of TGF-β receptor type II. J Biol Chem 2006;281:7765-74.
35. Stewart LV, Song K, Hsing AY, Danielpour D. Regulation of trespin expression by modulators of cell growth, differentiation, and apoptosis in prostatic epithelial cells. Exp Cell Res 2003;284:303-15.
36. Danielpour D. Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-β. J Cell Sci 1999;112:169-79.
37. Hsing AY, Kadomatsu K, Bonham MJ, Danielpour D. Regulation of apoptosis induced by transforming growth factor-β1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res 1996;56:5146-9.
38. Bhuiyan MM, Li Y, Banerjee S, et al. Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006;66:10064-72.
39. Chipuk JE, Bhat M, Hsing AY, Ma J, Danielpour D. Bcl-xL blocks transforming growth factor-β1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J Biol Chem 2001;276:26614-21.
40. Choi SG, Yi Y, Kim YS, et al. A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-β type II receptor. J Biol Chem 1998;273:110-7.
41. Bae HW, Geiser AG, Kim DH, et al. Characterization of the promoter region of the human transforming growth factor-β type II receptor gene. J Biol Chem 1995;270:29460-8.
42. Ko Y, Banerji SS, Liu Y, et al. Expression of transforming growth factor-β receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells. J Cell Physiol 1998;176:424-34.
43. Litvinov IV, Vander Griend DJ, Antony L, et al. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A 2006;103:15085-90.
44. Jiao J, Wang S, Qiao R, et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 2007;67:6083-91.